Ultragenyx Pharmaceutical (RARE) Stock Forecast & Price Target

Compare

963 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RARE Analyst Ratings

Strong Buy

15 Buy

1 Hold

0 Sell

Based on 16 analysts giving stock ratings to

Ultragenyx

Pharmaceutical

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RARE Stock 12 Month Forecast

Average Price Target

$84.38

▲(183.34% Upside)

Based on 16 Wall Street analysts offering 12 month price targets for Ultragenyx Pharmaceutical in the last 3 months. The average price target is $84.38 with a high forecast of $128.00 and a low forecast of $35.00. The average price target represents a 183.34% change from the last price of $29.78.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"27":"$27","78":"$78","129":"$129","52.5":"$52.5","103.5":"$103.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":128,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$128.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":84.38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$84.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$35.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[27,52.5,78,103.5,129],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.44,36.09846153846154,43.75692307692308,51.41538461538462,59.073846153846155,66.7323076923077,74.39076923076924,82.04923076923077,89.70769230769231,97.36615384615385,105.02461538461539,112.68307692307692,120.34153846153846,{"y":128,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.44,32.74307692307693,37.04615384615385,41.34923076923077,45.652307692307694,49.95538461538462,54.258461538461546,58.56153846153846,62.86461538461539,67.1676923076923,71.47076923076924,75.77384615384615,80.07692307692308,{"y":84.38,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.44,28.944615384615386,29.44923076923077,29.953846153846154,30.45846153846154,30.963076923076922,31.467692307692307,31.972307692307695,32.47692307692308,32.98153846153846,33.48615384615385,33.99076923076923,34.495384615384616,{"y":35,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":44.15,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.78,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.51,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.99,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.6,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.07,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.03,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.92,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.84,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.97,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.26,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$128.00

Average Price Target$84.38

Lowest Price Target$35.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Joseph Schwartz

Leerink Partners

―

Buy

―

Reiterated

08/18/25

Ultragenyx's Strategic Progress with DTX401 Gene Therapy Drives Buy Rating Amid Promising Market PotentialWe model the program with gross peak sales of ~$460M (US + 60% probability-of-success (PoS). Meanwhile, investor focus largely remains on the setrusumab program (osteogenesis imperfecta), with the final analysis of the Ph.3 ORBIT study (NCT05125809) expected around the end of the year. We remain Outperform on RARE. Reason for report: FLASH NOTE $25.81 Shares Outstanding (mil): 98.5 Market Capitalization (mil): $2,924.5 Joseph P. Schwartz (617) 918-4575 918-4552 Company Information and Leerink Partners LLC Research. Basic GAAP EPS Presented. Please refer to page 2 for Certification.ULTRAGENYX PHARMACEUTICAL INC.

Sami Corwin

William Blair

―

Buy

―

Reiterated

08/18/25

Ultragenyx Pharmaceutical: Promising Developments and Strategic Advancements Support Buy Rating

Allison Bratzel

Piper Sandler

$105

Buy

252.59%

Upside

Reiterated

08/08/25

Piper Sandler Remains a Buy on Ultragenyx Pharmaceutical (RARE)

Anupam Rama

J.P. Morgan

$116→$125

Buy

319.74%

Upside

Reiterated

08/08/25

Ultragenyx Pharmaceutical's Setrusumab: A Promising Buy with Potential for Significant Fracture Reduction in Osteogenesis Imperfecta

Joon Lee

Truist Financial

―

Buy

―

Reiterated

08/07/25

Truist Financial Remains a Buy on Ultragenyx Pharmaceutical (RARE)

Whitney Ijem

Canaccord Genuity

$136→$128

Buy

329.82%

Upside

Reiterated

08/07/25

Ultragenyx price target lowered to $128 from $136 at CanaccordUltragenyx price target lowered to $128 from $136 at Canaccord

Ram Selvaraju

H.C. Wainwright

$80

Buy

168.64%

Upside

Reiterated

08/06/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Yaron Werber

TD Cowen

$86

Buy

188.78%

Upside

Reiterated

08/06/25

Ultragenyx Pharmaceutical: Strong Q2 Results and Promising Future Justify Buy Rating

Luca Issi

RBC Capital

$77

Buy

158.56%

Upside

Reiterated

08/06/25

RBC Capital Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE)

Tazeen Ahmad

Bank of America Securities

$80→$79

Buy

165.28%

Upside

Reiterated

07/15/25

Positive Outlook on Ultragenyx Pharmaceutical Despite Setback with UX111 Approval

Maxwell Skor

Morgan Stanley

$65→$55

Buy

84.69%

Upside

Reiterated

07/13/25

Ultragenyx price target lowered to $55 from $65 at Morgan StanleyUltragenyx price target lowered to $55 from $65 at Morgan Stanley

Liisa Bayko

Evercore ISI

$70

Buy

135.06%

Upside

Reiterated

07/10/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Salveen Richter

Goldman Sachs

$82

Buy

175.35%

Upside

Reiterated

07/10/25

Goldman Sachs Remains a Buy on Ultragenyx Pharmaceutical (RARE)

Laura Chico

Wedbush

$39→$35

Hold

17.53%

Upside

Reiterated

07/10/25

Wedbush Reaffirms Their Hold Rating on Ultragenyx Pharmaceutical (RARE)

Yigal Nochomovitz

Citi

$110

Buy

269.38%

Upside

Reiterated

07/09/25

Ultragenyx Pharmaceutical: Buy Rating Affirmed Amid ORBIT Trial Optimism and Undervalued Stock Price

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Joseph Schwartz

Leerink Partners

―

Buy

―

Reiterated

08/18/25

Sami Corwin

William Blair

―

Buy

―

Reiterated

08/18/25

Ultragenyx Pharmaceutical: Promising Developments and Strategic Advancements Support Buy Rating

Allison Bratzel

Piper Sandler

$105

Buy

252.59%

Upside

Reiterated

08/08/25

Piper Sandler Remains a Buy on Ultragenyx Pharmaceutical (RARE)

Anupam Rama

J.P. Morgan

$116→$125

Buy

319.74%

Upside

Reiterated

08/08/25

Ultragenyx Pharmaceutical's Setrusumab: A Promising Buy with Potential for Significant Fracture Reduction in Osteogenesis Imperfecta

Joon Lee

Truist Financial

―

Buy

―

Reiterated

08/07/25

Truist Financial Remains a Buy on Ultragenyx Pharmaceutical (RARE)

Whitney Ijem

Canaccord Genuity

$136→$128

Buy

329.82%

Upside

Reiterated

08/07/25

Ultragenyx price target lowered to $128 from $136 at CanaccordUltragenyx price target lowered to $128 from $136 at Canaccord

Ram Selvaraju

H.C. Wainwright

$80

Buy

168.64%

Upside

Reiterated

08/06/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Yaron Werber

TD Cowen

$86

Buy

188.78%

Upside

Reiterated

08/06/25

Ultragenyx Pharmaceutical: Strong Q2 Results and Promising Future Justify Buy Rating

Luca Issi

RBC Capital

$77

Buy

158.56%

Upside

Reiterated

08/06/25

RBC Capital Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE)

Tazeen Ahmad

Bank of America Securities

$80→$79

Buy

165.28%

Upside

Reiterated

07/15/25

Positive Outlook on Ultragenyx Pharmaceutical Despite Setback with UX111 Approval

Maxwell Skor

Morgan Stanley

$65→$55

Buy

84.69%

Upside

Reiterated

07/13/25

Ultragenyx price target lowered to $55 from $65 at Morgan StanleyUltragenyx price target lowered to $55 from $65 at Morgan Stanley

Liisa Bayko

Evercore ISI

$70

Buy

135.06%

Upside

Reiterated

07/10/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Salveen Richter

Goldman Sachs

$82

Buy

175.35%

Upside

Reiterated

07/10/25

Goldman Sachs Remains a Buy on Ultragenyx Pharmaceutical (RARE)

Laura Chico

Wedbush

$39→$35

Hold

17.53%

Upside

Reiterated

07/10/25

Wedbush Reaffirms Their Hold Rating on Ultragenyx Pharmaceutical (RARE)

Yigal Nochomovitz

Citi

$110

Buy

269.38%

Upside

Reiterated

07/09/25

Ultragenyx Pharmaceutical: Buy Rating Affirmed Amid ORBIT Trial Optimism and Undervalued Stock Price

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ultragenyx Pharmaceutical

1 Month

xxx

Success Rate

13/20 ratings generated profit

Average Return

+4.21%

reiterated a xxx

rating 18 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 65.00% of your transactions generating a profit, with an average return of +4.21% per trade.

3 Months

xxx

Success Rate

11/20 ratings generated profit

Average Return

+1.50%

reiterated a xxx

rating 18 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 55.00% of your transactions generating a profit, with an average return of +1.50% per trade.

1 Year

Joon LeeTruist Financial

Success Rate

8/20 ratings generated profit

Average Return

+3.54%

reiterated a buy rating 18 days ago

Copying Joon Lee's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of +3.54% per trade.

2 Years

xxx

Success Rate

11/29 ratings generated profit

Average Return

+6.02%

reiterated a xxx

rating 19 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 37.93% of your transactions generating a profit, with an average return of +6.02% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RARE Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RARE has received 36 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. RARE average Analyst price target in the past 3 months is 84.38.

Each month's total comprises the sum of three months' worth of ratings.

RARE Financial Forecast

RARE Earnings Forecast

Next quarter’s earnings estimate for RARE is -$1.23 with a range of -$1.39 to -$0.98. The previous quarter’s EPS was -$1.17. RARE beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.02% of the time in the same period. In the last calendar year RARE has Outperformed its overall industry.

RARE Sales Forecast

Next quarter’s sales forecast for RARE is $167.02M with a range of $158.00M to $175.25M. The previous quarter’s sales results were $166.50M. RARE beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.29% of the time in the same period. In the last calendar year RARE has Outperformed its overall industry.

RARE Stock Forecast FAQ

What is RARE’s average 12-month price target, according to analysts?

Based on analyst ratings, Ultragenyx Pharmaceutical’s 12-month average price target is 84.38.

What is RARE’s upside potential, based on the analysts’ average price target?

Ultragenyx Pharmaceutical has 183.34% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RARE a Buy, Sell or Hold?

Ultragenyx Pharmaceutical has a consensus rating of Strong Buy which is based on 15 buy ratings, 1 hold ratings and 0 sell ratings.

What is Ultragenyx Pharmaceutical’s price target?

The average price target for Ultragenyx Pharmaceutical is 84.38. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $128.00 ,the lowest forecast is $35.00. The average price target represents 183.34% Increase from the current price of $29.78.

What do analysts say about Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of RARE?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Ultragenyx Pharmaceutical (RARE) Stock Forecast & Price Target

RARE Analyst Ratings

RARE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Ultragenyx Pharmaceutical

RARE Analyst Recommendation Trends

RARE Financial Forecast

RARE Earnings Forecast

RARE Sales Forecast

RARE Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts